Several brokerages have shared their views on Dr Lal Path Labs. Here’s what they are saying:
- Goldman Sachs: Goldman Sachs has maintained its sell call on Dr Lal Path and raised the share price target to ₹2,675 from ₹2,450, implying a 17.6% downside from the CMP of ₹3,250. The brokerage expects slower growth and sees patient volume growth remaining below pre-COVID levels.
- UBS: UBS has maintained a buy rating with a share price target of ₹3,500, implying a 7.7% upside from the CMP of ₹3,250. The brokerage highlighted strong Q2 results and expects revenue growth driven by increasing volumes, with further lab expansions anticipated.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Please consult a qualified financial advisor before making any investment decisions.
